Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;11(4):417-23.
doi: 10.1097/COH.0000000000000287.

Persistent HIV-1 replication during antiretroviral therapy

Affiliations
Review

Persistent HIV-1 replication during antiretroviral therapy

Javier Martinez-Picado et al. Curr Opin HIV AIDS. 2016 Jul.

Abstract

Purpose of review: The present review will highlight some of the recent findings regarding the capacity of HIV-1 to replicate during antiretroviral therapy (ART).

Recent findings: Although ART is highly effective at inhibiting HIV replication, it is not curative. Several mechanisms contribute to HIV persistence during ART, including HIV latency, immune dysfunction, and perhaps persistent low-level spread of the virus to uninfected cells (replication). The success in curing HIV will depend on efficiently targeting these three aspects. The degree to which HIV replicates during ART remains controversial. Most studies have failed to find any evidence of HIV evolution in blood, even with samples collected over many years, although a recent very intensive study of three individuals suggested that the virus population does shift, at least during the first few months of therapy. Stronger but still not definitive evidence for replication comes from a series of studies in which standard regimens were intensified with an integration inhibitor, resulting in changes in episomal DNA (blood) and cell-associated RNA (tissue). Limited drug penetration within tissues and the presence of immune sanctuaries have been argued as potential mechanisms allowing HIV to spread during ART. Mathematical models suggest that HIV replication and evolution is possible even without the selection of fully drug-resistant variants. As persistent HIV replication could have clinical consequences and might limit the efficacy of curative interventions, determining if HIV replicates during ART and why, should remain a key focus of the HIV research community.

Summary: Residual viral replication likely persists in lymphoid tissues, at least in a subset of individuals. Abnormal levels of immune activation might contribute to sustain virus replication.

PubMed Disclaimer

Figures

Box 1
Box 1
no caption available
FIGURE 1
FIGURE 1
Suggested mechanisms of HIV residual replication during antiretroviral therapy (ART). Limited drug penetration within tissues, the presence of immune sanctuaries, cell-to-cell viral transmission, and abnormal levels of immune activation and inflammation have been argued as potential mechanisms allowing HIV to spread and evolve during ART.

References

    1. Hockett RD, Kilby JM, et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 1999; 189:1545–1554. - PMC - PubMed
    1. Hatano H, Delwart EL, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83:329–335. - PMC - PubMed
    1. Mens H, Kearney M, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010; 84:12971–12981. - PMC - PubMed
    1. Chun TW, Shawn Justement J, et al. Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis 2013; 208:1443–1447. - PMC - PubMed
    1. Hatano H, Yukl SA, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9:e1003691. - PMC - PubMed

Substances